These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35863608)

  • 1. A comparison of primary laser versus laser after anti-vascular endothelial growth factor for type 1 retinopathy of prematurity.
    Lajoie JE; Pacheco RR; Shah V; Tauber KA; Binenbaum G; Barry GP
    J AAPOS; 2022 Aug; 26(4):191.e1-191.e4. PubMed ID: 35863608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retinal Detachment after Treatment of Retinopathy of Prematurity with Laser versus Intravitreal Anti-Vascular Endothelial Growth Factor.
    Barry GP; Yu Y; Ying GS; Tomlinson LA; Lajoie J; Fisher M; Binenbaum G;
    Ophthalmology; 2021 Aug; 128(8):1188-1196. PubMed ID: 33387554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term retinal detachment risk after treatment of type 1 retinopathy of prematurity with laser photocoagulation versus intravitreal bevacizumab.
    Barry GP; Tauber KA; Fisher M; Greenberg S; Zobal-Ratner J; Binenbaum G
    J AAPOS; 2019 Oct; 23(5):260.e1-260.e4. PubMed ID: 31513902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined Vitrectomy and Anti-VEGF Treatment for Stage 4 Retinopathy of Prematurity With Extensive Neovascular Proliferation.
    Chandra P; Kumawat D; Agarwal D; Chawla R
    J Pediatr Ophthalmol Strabismus; 2020 Jan; 57(1):61-66. PubMed ID: 31972043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the Efficacy Between Intravitreal Aflibercept and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity.
    Ekinci DY; Çelik K
    J Pediatr Ophthalmol Strabismus; 2020 Jan; 57(1):54-60. PubMed ID: 31972042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anterior segment ischemia after laser for retinopathy of prematurity previously treated with antivascular endothelial growth factor.
    Castillejo Becerra CM; Mansukhani SA; Sagaser SD; Mammo DA; Bothun ED; Quiram PA; Mohney BG
    J AAPOS; 2021 Jun; 25(3):155.e1-155.e5. PubMed ID: 34044115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
    Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R
    Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extending Peripheral Retinal Vascularization in Retinopathy of Prematurity Through Regulation of VEGF Signaling.
    Sauer L; Chandler M; Hartnett ME
    Am J Ophthalmol; 2024 Apr; 260():190-199. PubMed ID: 38141904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors associated with refractive outcome in children treated with bevacizumab for retinopathy of prematurity: the importance of retinal vascularization.
    Bayramoglu SE; Sayin N
    Int Ophthalmol; 2022 Oct; 42(10):3199-3210. PubMed ID: 35579771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
    Sankar MJ; Sankar J; Chandra P
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD009734. PubMed ID: 29308602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.
    Hwang CK; Hubbard GB; Hutchinson AK; Lambert SR
    Ophthalmology; 2015 May; 122(5):1008-15. PubMed ID: 25687024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of optical coherence tomography biomarkers to differentiate favourable and unfavourable responders to intravitreal anti-vascular endothelial growth factor treatment in retinopathy of prematurity.
    Belenje A; Reddy RU; Parmeswarappa DC; Padhi TR; Subbarao B; Jalali S
    Eye (Lond); 2024 Apr; 38(6):1097-1103. PubMed ID: 37968517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RATES AND RISK FACTORS FOR RECURRENCE OF RETINOPATHY OF PREMATURITY AFTER LASER OR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY.
    Ling KP; Liao PJ; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
    Retina; 2020 Sep; 40(9):1793-1803. PubMed ID: 31800460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Morphological outcome and indication for laser following intravitreal bevacizumab monotherapy for posterior retinopathy of prematurity.
    Sindal MD; Nagesha CK; Yadav D; Fazal R
    Lasers Med Sci; 2022 Jul; 37(5):2501-2508. PubMed ID: 35106690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic laser versus continued surveillance after initial bevacizumab treatment for retinopathy of prematurity.
    Hong GJ; Stinnett SS; Freedman SF; Wallace DK; Prakalapakorn SG
    J AAPOS; 2021 Jun; 25(3):177-180. PubMed ID: 33964453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reactivation of retinopathy of prematurity six years after intravitreal injection of bevacizumab.
    Yasin A; Sinha S; Smith R; Jain SF; Hejkal T; Rychwalski P
    J AAPOS; 2023 Aug; 27(4):236-239. PubMed ID: 37451499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential Short Interval Anti-VEGF for the Treatment of Stage 4 Retinopathy of Prematurity.
    Hamichi SE; Saigal K; Anzaldo EF; Gold A; Berrocal AM; Murray TG
    Ophthalmic Surg Lasers Imaging Retina; 2022 Mar; 53(3):159-163. PubMed ID: 35272561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity.
    Karkhaneh R; Khodabande A; Riazi-Eafahani M; Roohipoor R; Ghassemi F; Imani M; Dastjani Farahani A; Ebrahimi Adib N; Torabi H
    Acta Ophthalmol; 2016 Sep; 94(6):e417-20. PubMed ID: 27009449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FLUORESCEIN ANGIOGRAPHIC EVALUATION OF PERIPHERAL RETINAL VASCULATURE AFTER PRIMARY INTRAVITREAL RANIBIZUMAB FOR RETINOPATHY OF PREMATURITY.
    Harper CA; Wright LM; Young RC; Read SP; Chang EY
    Retina; 2019 Apr; 39(4):700-705. PubMed ID: 29300248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison.
    Han J; Kim SE; Lee SC; Lee CS
    Acta Ophthalmol; 2018 Jun; 96(4):e475-e478. PubMed ID: 27011262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.